Kornitzer Capital Management Inc. KS Purchases 22,950 Shares of Edwards Lifesciences Co. (NYSE:EW)

Kornitzer Capital Management Inc. KS increased its stake in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 18.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 149,001 shares of the medical research company's stock after purchasing an additional 22,950 shares during the period. Kornitzer Capital Management Inc. KS's holdings in Edwards Lifesciences were worth $11,361,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Castleview Partners LLC bought a new stake in shares of Edwards Lifesciences during the first quarter valued at approximately $25,000. Compass Wealth Management LLC bought a new stake in Edwards Lifesciences during the 4th quarter valued at $31,000. Turtle Creek Wealth Advisors LLC acquired a new position in Edwards Lifesciences during the 4th quarter worth $34,000. Janiczek Wealth Management LLC grew its stake in shares of Edwards Lifesciences by 108.6% in the third quarter. Janiczek Wealth Management LLC now owns 582 shares of the medical research company's stock worth $40,000 after purchasing an additional 303 shares in the last quarter. Finally, Operose Advisors LLC increased its holdings in shares of Edwards Lifesciences by 247.0% during the third quarter. Operose Advisors LLC now owns 635 shares of the medical research company's stock valued at $44,000 after purchasing an additional 452 shares during the period. Institutional investors and hedge funds own 79.46% of the company's stock.

Edwards Lifesciences Trading Down 0.6 %

Shares of Edwards Lifesciences stock traded down $0.51 during trading on Friday, hitting $85.94. The stock had a trading volume of 3,895,701 shares, compared to its average volume of 2,826,513. The stock has a 50 day simple moving average of $90.15 and a 200 day simple moving average of $78.37. The company has a market capitalization of $51.73 billion, a PE ratio of 37.37, a P/E/G ratio of 4.29 and a beta of 1.05. The company has a quick ratio of 2.40, a current ratio of 3.38 and a debt-to-equity ratio of 0.09. Edwards Lifesciences Co. has a 1 year low of $60.57 and a 1 year high of $96.12.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its earnings results on Tuesday, February 6th. The medical research company reported $0.64 earnings per share for the quarter, hitting the consensus estimate of $0.64. The business had revenue of $1.53 billion for the quarter, compared to the consensus estimate of $1.50 billion. Edwards Lifesciences had a net margin of 23.35% and a return on equity of 23.56%. The firm's quarterly revenue was up 13.3% compared to the same quarter last year. During the same period last year, the firm posted $0.64 earnings per share. On average, research analysts expect that Edwards Lifesciences Co. will post 2.76 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have commented on EW. Citigroup boosted their price target on shares of Edwards Lifesciences from $90.00 to $98.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 3rd. Bank of America upgraded shares of Edwards Lifesciences from a "neutral" rating to a "buy" rating in a research report on Thursday, March 7th. Royal Bank of Canada boosted their price target on shares of Edwards Lifesciences from $95.00 to $101.00 and gave the stock an "outperform" rating in a research report on Monday, April 15th. OTR Global upgraded shares of Edwards Lifesciences from a "mixed" rating to a "positive" rating in a research report on Tuesday, March 26th. Finally, Mizuho boosted their price target on shares of Edwards Lifesciences from $95.00 to $105.00 and gave the stock a "buy" rating in a research report on Thursday, April 11th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat.com, Edwards Lifesciences currently has an average rating of "Moderate Buy" and a consensus target price of $91.73.

Insider Activity at Edwards Lifesciences

In related news, CFO Scott B. Ullem sold 7,255 shares of the business's stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $78.29, for a total transaction of $567,993.95. Following the transaction, the chief financial officer now directly owns 19,248 shares of the company's stock, valued at $1,506,925.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, Director Michael A. Mussallem sold 29,350 shares of the business's stock in a transaction that occurred on Thursday, April 4th. The shares were sold at an average price of $92.42, for a total transaction of $2,712,527.00. Following the transaction, the director now directly owns 4,486 shares of the company's stock, valued at $414,596.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Scott B. Ullem sold 7,255 shares of the business's stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $78.29, for a total transaction of $567,993.95. Following the completion of the sale, the chief financial officer now directly owns 19,248 shares of the company's stock, valued at $1,506,925.92. The disclosure for this sale can be found here. Over the last three months, insiders have sold 194,004 shares of company stock valued at $17,166,254. Corporate insiders own 1.29% of the company's stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.